Downregulation of Hepatic PPA1 Protects Against Obesity by Elevating FGF21 Production via eIF2α Phosphorylation
Diabetes · 2026
DOI: 10.2337/db25-0655 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, 2026. Verfasst von Yue Sun und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Key Laboratory of the Molecular Targets of Metabolic Diseases and Intervention of Jiangsu Province, Department of Biochemistry and Molecular Biol…. Hauptthemen laut MEDLINE: Fibroblast Growth Factors, Obesity, Liver, Eukaryotic Initiation Factor-2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Chronic overnutrition promotes excessive hepatic triglyceride accumulation, subsequently leading to insulin resistance and systemic metabolic dysfunction. Inorganic pyrophosphatase 1 (PPA1), an enzyme that hydrolyzes inorganic pyrophosphate, plays a key role in driving synthetic biochemical reactions. Here, we identified PPA1 as a novel regulator of systemic energy expenditure that functions by controlling hepatic production of fibroblast growth factor 21 (FGF21). FGF21 is a hormone predominantly secreted by the liver that protects against obesity by enhancing whole-body energy expenditure. Although nutritional states and various transcription factors are known to regulate hepatic FGF21 expression, the underlying mechanisms remain elusive. In this study, we demonstrate that hepatic-specific deletion of PPA1 effectively attenuates high-fat diet–induced obesity, reduces hepatic lipid deposition, and improves systemic insulin sensitivity in vivo. PPA1 ablation in the liver significantly elevates circulating FGF21 levels and increases whole-body energy expenditure by promoting adipose tissue browning and thermogenesis. Knockdown of hepatic FGF21 expression partially counteracts the protective effect conferred by PPA1 deficiency. Mechanistically, hepatic PPA1 deficiency elevates FGF21 through the GCN2/eIF2α/ATF4 pathway, a process that is dependent on the loss of its enzymatic activity. Our findings not only establish PPA1 as a critical regulator of systemic energy metabolism but also identify it as a novel modulator of FGF21, highlighting its potential as a therapeutic target for obesity and related metabolic disorders. Article Highlights Pyrophosphatase 1 (PPA1) is upregulated in livers of high-fat diet–induced obese mice and metabolic dysfunction–associated steatotic liver disease patients. Hepatic PPA1 deletion protects mice against high-fat diet–induced obesity and related metabolic disorders by promoting whole-body energy expenditure. Deficiency of hepatic PPA1 expression facilitates fibroblast growth factor 21 production by activating the GCN2/eIF2α/ATF4 signaling pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Key Laboratory of the Molecular Targets of Metabolic Diseases and Intervention of Jiangsu Province, Department of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, Jiangsu, China.
- Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
ORCID-Profile: Xiao Han, Haiyan Lin, Ye Yin
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Sun, Y., Zhang, J., Su, Y., Wu, T., Chen, J., Yang, N., Han, X., Lin, H., & Yin, Y. (2026). Downregulation of Hepatic PPA1 Protects Against Obesity by Elevating FGF21 Production via eIF2α Phosphorylation. Diabetes. https://doi.org/10.2337/db25-0655
Vancouver
Sun Y, Zhang J, Su Y, Wu T, Chen J, Yang N, et al. Downregulation of Hepatic PPA1 Protects Against Obesity by Elevating FGF21 Production via eIF2α Phosphorylation. Diabetes. 2026. doi:10.2337/db25-0655
BibTeX
@article{Sun2026,
author = {Sun, Yue and Zhang, Jinfu and Su, Yuanyuan and Wu, Tiancheng and Chen, Jiaqi and Yang, Nan and Han, Xiao and Lin, Haiyan and Yin, Ye},
title = {Downregulation of Hepatic PPA1 Protects Against Obesity by Elevating FGF21 Production via eIF2α Phosphorylation},
journal = {Diabetes},
year = {2026},
doi = {10.2337/db25-0655}
}
EUVIMED